CD82

Across TCGA pan-cancer cohorts, CD82 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CD82 data layer compared with 19 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher CD82 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated CD82 expression acts as an unfavorable survival marker, although some lineages such as HNSC and UCEC show a favorable association.

HNSC, CCRCC, and COAD are the cancer types where CD82 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.843	0.699	.006	20	view →
CCRCC	DFS	Median	II,III,IV	0.128	0.952	.003	15	view →
COAD	DFS	Median	III,IV	0.886	1.000	.024	12	view →
GBM	OS	Quartile	All	0.213	0.553	.024	4	view →
LUAD	DFS	Median	All	0.681	0.912	.034	3	view →
UCEC	OS	Tertile	All	1.000	0.893	.037	2	view →
LSCC	OS	Quartile	II,III,IV	0.590	0.917	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CD82–HNSC (DFS)

Open the HNSC breakdown →